Promedior has developed a novel platform to treat fibrotic diseases which focuses on targeting the specific monocyte-derived cell populations that orchestrate fibrosis and tissue remodeling. This new paradigm for treating fibrotic diseases is upstream and dominant to traditional approaches and takes advantage of universal biology common to all tissues to promote healing without scarring.
Learn more about Promedior's research and development efforts.